Biotech
-
Peter Marks, FDA’s top vaccine official, resigns
In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed “misinformation and…
Read More » -
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy
The biotech is slashing a third of its workforce and more than half of its executive team in moves it…
Read More » -
Merck bets $200M on a new type of heart pill
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic…
Read More » -
Delayed CDC meeting on vaccines is rescheduled to April
A panel of CDC advisers, who had been set to meet in February, will discuss the current measles outbreak as…
Read More » -
AstraZeneca deepens China investment; Editas loses CFO to Dyne
The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash…
Read More » -
Optum Rx says it will eliminate some prior authorization requirements
The PBM plans to stop requiring coverage reauthorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and many MS…
Read More » -
Taiho buys Swiss biotech and its ADC tech for $400M
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is…
Read More » -
FDA sets flu shot recommendations without input of outside advisers
The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting that's typically…
Read More » -
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a…
Read More » -
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.
Read More »